PET predicts GI cancer's early response to chemo

Article

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

F-18 FDG-PET can tell which patients will respond to neoadjuvant chemotherapy for advanced adenocarcinoma of the esophagogastric junction only two weeks after they begin treatment, according to a study released at the 2007 SNM meeting.

German investigators evaluated 110 patients who underwent FDG-PET to assess response to chemotherapy. Researchers defined as responders patients with 35% or greater decrease in tumor standardized uptake value after two weeks of treatment. Responders went on chemotherapy for 12 weeks before surgery, while nonresponders discontinued treatment and proceeded to surgery right away.

Researchers found statistically significant evidence (p < .002) that responders survived about twice as long as nonresponders during a median follow-up of 2.3 years.

Recent Videos
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Employing AI in Detecting Subdural Hematomas on Head CTs: An Interview with Jeremy Heit, MD, PhD
Related Content
© 2025 MJH Life Sciences

All rights reserved.